Ribavirin Teva Pharma B.V.
ribavirin
Table of contents
Overview
The marketing authorisation for Ribavirin Teva Pharma B. V. has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Ribavirin Teva Pharma B.V.
|
| Agency product number |
EMEA/H/C/001064
|
| Active substance |
Ribavirin
|
| International non-proprietary name (INN) or common name |
ribavirin
|
| Therapeutic area (MeSH) |
Hepatitis C, Chronic
|
| Anatomical therapeutic chemical (ATC) code |
J05AP01
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Teva B.V.
|
| Revision |
14
|
| Date of issue of marketing authorisation valid throughout the European Union |
01/07/2009
|
| Contact address |
Swensweg 5 |
Product information
22/06/2021 Ribavirin Teva Pharma B.V. - EMEA/H/C/001064 - IA/0023
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of
chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).
Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of
chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not
previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).